Now showing items 1-1 of 1
Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population
Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to ...